Daniel E. Singer

72.3k total citations · 23 hit papers
439 papers, 52.6k citations indexed

About

Daniel E. Singer is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Internal Medicine. According to data from OpenAlex, Daniel E. Singer has authored 439 papers receiving a total of 52.6k indexed citations (citations by other indexed papers that have themselves been cited), including 275 papers in Cardiology and Cardiovascular Medicine, 105 papers in Epidemiology and 92 papers in Internal Medicine. Recurrent topics in Daniel E. Singer's work include Atrial Fibrillation Management and Outcomes (252 papers), Cardiac Arrhythmias and Treatments (112 papers) and Venous Thromboembolism Diagnosis and Management (92 papers). Daniel E. Singer is often cited by papers focused on Atrial Fibrillation Management and Outcomes (252 papers), Cardiac Arrhythmias and Treatments (112 papers) and Venous Thromboembolism Diagnosis and Management (92 papers). Daniel E. Singer collaborates with scholars based in United States, United Kingdom and Germany. Daniel E. Singer's co-authors include Yuchiao Chang, Alan S. Go, Elaine M. Hylek, Lori Henault, Joe V. Selby, Jonathan L. Halperin, Kathleen A. Phillips, Kenneth W. Mahaffey, Jonathan P. Piccini and Steven J. Atlas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Daniel E. Singer

422 papers receiving 50.5k citations

Hit Papers

Rivaroxaban versus Warfarin in... 1984 2026 1998 2012 2011 2001 1997 1990 2013 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
    2011 6.6k citations Manesh R. Patel, Kenneth W. Mahaffey et al. New England Journal of Medicine profile →
  2. Prevalence of Diagnosed Atrial Fibrillation in Adults
    2001 4.8k citations Alan S. Go, Elaine M. Hylek et al. profile →
  3. A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
    1997 3.4k citations Daniel E. Singer et al. New England Journal of Medicine profile →
  4. The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
    1990 1.1k citations Daniel E. Singer New England Journal of Medicine profile →
  5. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population
    2013 949 citations Daniel E. Singer et al. profile →
  6. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
    2003 943 citations Elaine M. Hylek, Alan S. Go et al. New England Journal of Medicine profile →
  7. Antithrombotic Therapy for Atrial Fibrillation
    2012 697 citations Daniel E. Singer, Margaret C. Fang et al. profile →
  8. Assessing Health-Related Quality of Life in Patients With Sciatica
    1995 658 citations Steven J. Atlas, Daniel E. Singer et al. profile →
  9. A New Risk Scheme to Predict Warfarin-Associated Hemorrhage
    2011 638 citations Margaret C. Fang, Alan S. Go et al. Journal of the American College of Cardiology profile →
  10. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk
    2009 611 citations Daniel E. Singer, Paul Ziegler et al. Circulation Arrhythmia and Electrophysiology profile →
  11. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic Atrial Fibrillation
    1996 578 citations Elaine M. Hylek, Steven J. Skates et al. New England Journal of Medicine profile →
  12. Antithrombotic Therapy in Atrial Fibrillation
    2008 569 citations Daniel E. Singer, Margaret C. Fang et al. profile →
  13. Anticoagulation Therapy for Stroke Prevention in Atrial Fibrillation
    2003 553 citations Alan S. Go, Elaine M. Hylek et al. profile →
  14. The Clinical Information Value of the Glycosylated Hemoglobin Assay
    1984 546 citations Daniel E. Singer et al. New England Journal of Medicine profile →
  15. Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation
    2002 534 citations Carl van Walraven, Robert G. Hart et al. profile →
  16. The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
    2009 500 citations Daniel E. Singer et al. profile →
  17. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
    2011 440 citations Keith A.A. Fox, Jonathan P. Piccini et al. profile →
  18. Mortality Among Homeless Adults in Boston
    2013 424 citations Bianca Porneala, Daniel E. Singer et al. profile →
  19. The Unmet Health Care Needs of Homeless Adults: A National Study
    2010 412 citations Daniel E. Singer et al. profile →
  20. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes
    2016 353 citations Benjamin A. Steinberg, Kenneth W. Mahaffey et al. Journal of the American College of Cardiology profile →
  21. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
    2014 321 citations Jonathan L. Halperin, Graeme J. Hankey et al. Circulation profile →
  22. Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study
    2022 173 citations Steven A. Lubitz, Anthony Z. Faranesh et al. Circulation profile →
  23. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates
    2022 171 citations Daniel E. Singer et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel E. Singer United States 108 33.3k 12.6k 12.0k 4.9k 3.5k 439 52.6k
Keith A.A. Fox United Kingdom 109 47.7k 1.4× 4.8k 0.4× 12.1k 1.0× 15.5k 3.2× 2.9k 0.8× 834 59.8k
Elliott M. Antman United States 108 49.4k 1.5× 3.9k 0.3× 9.6k 0.8× 17.3k 3.6× 2.5k 0.7× 527 61.0k
Christian Torp‐Pedersen Denmark 107 32.3k 1.0× 5.1k 0.4× 3.1k 0.3× 7.4k 1.5× 1.6k 0.5× 1.3k 52.4k
Alan S. Go United States 93 25.3k 0.8× 6.5k 0.5× 4.9k 0.4× 5.6k 1.2× 2.8k 0.8× 483 47.4k
Gregory Y.H. Lip United Kingdom 148 93.1k 2.8× 18.4k 1.5× 26.1k 2.2× 11.3k 2.3× 6.3k 1.8× 3.0k 120.3k
Christopher B. Granger United States 119 49.5k 1.5× 5.6k 0.4× 7.3k 0.6× 13.8k 2.8× 2.6k 0.7× 846 63.9k
Eugene Braunwald United States 127 50.8k 1.5× 6.7k 0.5× 8.0k 0.7× 30.6k 6.3× 5.3k 1.5× 703 77.3k
Gunnar Gislason Denmark 85 15.7k 0.5× 4.2k 0.3× 3.0k 0.2× 5.4k 1.1× 1.1k 0.3× 926 31.4k
Christopher P. Cannon United States 125 38.0k 1.1× 6.5k 0.5× 3.9k 0.3× 27.9k 5.7× 5.3k 1.5× 879 67.5k
Jeffrey L. Anderson United States 91 20.7k 0.6× 5.5k 0.4× 1.9k 0.2× 8.4k 1.7× 1.8k 0.5× 527 36.8k

Countries citing papers authored by Daniel E. Singer

Since Specialization
Citations

This map shows the geographic impact of Daniel E. Singer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Singer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Singer more than expected).

Fields of papers citing papers by Daniel E. Singer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Singer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Singer. The network helps show where Daniel E. Singer may publish in the future.

Co-authorship network of co-authors of Daniel E. Singer

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Singer. A scholar is included among the top collaborators of Daniel E. Singer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Singer. Daniel E. Singer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lubitz, Steven A., Michael V. McConnell, Caitlin Selvaggi, et al.. (2025). Wearable Irregular Heart Rhythm Detection Recurrences and Electrocardiographic Atrial Fibrillation Confirmation: The Fitbit Heart Study. Circulation Arrhythmia and Electrophysiology. 18(7). e013565–e013565.
2.
Lópes, Renato D., Steven J. Atlas, Alan S. Go, et al.. (2024). Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. Journal of the American College of Cardiology. 84(21). 2073–2084. 17 indexed citations
3.
Ashburner, Jeffrey M., Yuchiao Chang, Bianca Porneala, et al.. (2024). Predicting post-stroke cognitive impairment using electronic health record data. International Journal of Stroke. 19(8). 898–906. 3 indexed citations
4.
Lin, Kueiyu Joshua, Daniel E. Singer, Jerry Avorn, et al.. (2024). Patient Characteristics Associated With Using Transcatheter Left Atrial Appendage Occlusion Versus Oral Anticoagulants for Atrial Fibrillation. Circulation Cardiovascular Quality and Outcomes. 17(3). e010279–e010279. 3 indexed citations
5.
Go, Alan S., Sana M. Al‐Khatib, Patrice Desvigne‐Nickens, et al.. (2023). Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke. 54(3). 4 indexed citations
6.
Lubitz, Steven A., Steven J. Atlas, Jeffrey M. Ashburner, et al.. (2022). Screening for Atrial Fibrillation in Older Adults at Primary Care Visits: VITAL-AF Randomized Controlled Trial. Circulation. 145(13). 946–954. 63 indexed citations
7.
8.
Borowsky, Leila H., Susan Regan, Yuchiao Chang, et al.. (2017). First Diagnosis of Atrial Fibrillation at the Time of Stroke. Cerebrovascular Diseases. 43(3-4). 192–199. 41 indexed citations
9.
Turakhia, Mintu P., Paul Ziegler, Susan Schmitt, et al.. (2015). Atrial Fibrillation Burden and Short-Term Risk of Stroke. Circulation Arrhythmia and Electrophysiology. 8(5). 1040–1047. 143 indexed citations
10.
11.
Steinberg, Benjamin A., Anne S. Hellkamp, Yuliya Lokhnygina, et al.. (2014). Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm. 11(6). 925–932. 55 indexed citations
12.
Cyr, Derek D., Yuliya Lokhnygina, Richard C. Becker, et al.. (2014). OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL. Journal of the American College of Cardiology. 63(12). A371–A371. 2 indexed citations
13.
Diepen, Sean van, Anne S. Hellkamp, Manesh R. Patel, et al.. (2013). Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation Heart Failure. 6(4). 740–747. 83 indexed citations
14.
Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, et al.. (2012). Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation. 127(2). 224–232. 375 indexed citations
15.
Piccini, Jonathan P., Susanna R. Stevens, Yuliya Lokhnygina, et al.. (2012). Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. Circulation. 126(suppl_21). 6 indexed citations
16.
Patel, Manesh R., Kenneth W. Mahaffey, Jyotsna Garg, et al.. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 365(10). 883–891. 6637 indexed citations breakdown →
17.
Walraven, Carl van, Robert G. Hart, Stuart J. Connolly, et al.. (2009). Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation. Stroke. 40(4). 1410–1416. 234 indexed citations
18.
Go, Alan S., Margaret C. Fang, Natalia Udaltsova, et al.. (2009). Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation. Circulation. 119(10). 1363–1369. 319 indexed citations
19.
Hylek, Elaine M., Steven J. Skates, Mary A. Sheehan, & Daniel E. Singer. (1997). An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Patients With Nonrheumatic Atrial Fibrillation. ACC Current Journal Review. 2(6). 87. 8 indexed citations
20.
Burstin, Helen, et al.. (1993). Sociodemographic determinants in the hospitalization decision: Evaluation of an emergency department interhospital transfer policy. Annals of Emergency Medicine. 22(5). 813–818. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keith A.A. Fox Breakdown of academic impact, for papers by Elliott M. Antman Breakdown of academic impact, for papers by Christian Torp‐Pedersen Breakdown of academic impact, for papers by Alan S. Go Breakdown of academic impact, for papers by Gregory Y.H. Lip Breakdown of academic impact, for papers by Christopher B. Granger Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Gunnar Gislason Breakdown of academic impact, for papers by Christopher P. Cannon Breakdown of academic impact, for papers by Jeffrey L. Anderson
Rankless by CCL
2026